Literature DB >> 31477606

Recommendations for Prevention and Control of Influenza in Children, 2019-2020.

.   

Abstract

This statement updates the recommendations of the American Academy of Pediatrics for the routine use of influenza vaccines and antiviral medications in the prevention and treatment of influenza in children during the 2019-2020 season. The American Academy of Pediatrics continues to recommend routine influenza immunization of all children without medical contraindications, starting at 6 months of age. Any licensed, recommended, age-appropriate vaccine available can be administered, without preference of one product or formulation over another. Antiviral treatment of influenza with any licensed, recommended, age-appropriate influenza antiviral medication continues to be recommended for children with suspected or confirmed influenza, particularly those who are hospitalized, have severe or progressive disease, or have underlying conditions that increase their risk of complications of influenza.
Copyright © 2019 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31477606     DOI: 10.1542/peds.2019-2478

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  12 in total

1.  Steroid Sensitive Nephrotic Syndrome: Revised Guidelines.

Authors:  Aditi Sinha; Arvind Bagga; Sushmita Banerjee; Kirtisudha Mishra; Amarjeet Mehta; Indira Agarwal; Susan Uthup; Abhijeet Saha; Om Prakash Mishra
Journal:  Indian Pediatr       Date:  2021-03-20       Impact factor: 1.411

2.  Epidemiology of Influenza Viruses and Viruses Causing Influenza-Like Illness in Children Under 14 Years Old in the 2018-2019 Epidemic Season in Poland.

Authors:  Katarzyna Kondratiuk; Ewelina Hallmann; Katarzyna Łuniewska; Karol Szymański; Lidia Brydak
Journal:  Med Sci Monit       Date:  2021-05-09

Review 3.  Preparing for the 2020-2021 influenza season.

Authors:  Annabelle de St Maurice; Rachel Martin-Blais; Natasha Halasa
Journal:  Pediatr Transplant       Date:  2021-04-27

4.  Maintenance of a High Influenza Vaccination Rate and Improvement in Health Outcomes in a Pediatric Sickle Cell Disease Clinic.

Authors:  Zachary C Lo; Amy E Sobota
Journal:  J Pediatr Hematol Oncol       Date:  2022-01-01       Impact factor: 1.170

5.  H1N1 with fatal viral septicemia in a normal child: A case report.

Authors:  Ahmed Rezk Ahmed
Journal:  Respir Med Case Rep       Date:  2020-04-11

6.  One step closer to influenza vaccine inclusiveness.

Authors:  Mayla Sgrulletti; Giorgio Ottaviano; Maria Sangerardi; Loredana Chini; Rosa Maria Dellepiane; Baldassarre Martire; Davide Montin; Caterina Rizzo; Viviana Moschese
Journal:  Pediatr Allergy Immunol       Date:  2020-11       Impact factor: 6.377

7.  Influenza vaccine effectiveness in children: a retrospective study on eight post-pandemic seasons with trivalent inactivated vaccine.

Authors:  Maria Eugenia Colucci; Paola Affanni; Angelo Cantarelli; Luca Caruso; Maria Teresa Bracchi; Emanuela Capobianco; Roberta Zoni; Giulia Paini; Anna Odone; Mostafa Mohieldin Mohieldin Mahgoub Ibrahim; Licia Veronesi
Journal:  Acta Biomed       Date:  2020-04-10

8.  Protective Intranasal Immunization Against Influenza Virus in Infant Mice Is Dependent on IL-6.

Authors:  Elizabeth Ann Bonney; Kendall Krebs; Jihye Kim; Kirtika Prakash; Blake L Torrance; Laura Haynes; Mercedes Rincon
Journal:  Front Immunol       Date:  2020-10-28       Impact factor: 7.561

9.  A Reduced Dose Whole Virion Aluminum Adjuvanted Seasonal Influenza Vaccine Is Immunogenic, Safe, and Well Tolerated in Pediatric Patients.

Authors:  Zoltan Vajo; Gergely Balaton; Peter Vajo; Peter Torzsa
Journal:  Viruses       Date:  2021-03-18       Impact factor: 5.048

10.  Recommendations for Vaccination in Children with Atopic Dermatitis Treated with Dupilumab: A Consensus Meeting, 2020.

Authors:  Sylvia A Martinez-Cabriales; Mark G Kirchhof; Cora M Constantinescu; Luis Murguia-Favela; Michele L Ramien
Journal:  Am J Clin Dermatol       Date:  2021-06-02       Impact factor: 7.403

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.